Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial (Q46105770)

19 December 2017

title

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial (English)

1 reference

19 December 2017

0 references

Andrew D Goodman

1

1 reference

19 December 2017

Theodore R Brown

2

1 reference

19 December 2017

Lauren B Krupp

3

1 reference

19 December 2017

Randall T Schapiro

4

1 reference

19 December 2017

Steven R Schwid

5

1 reference

19 December 2017

Ron Cohen

6

1 reference

19 December 2017

Lawrence N Marinucci

7

1 reference

19 December 2017

Andrew R Blight

8

1 reference

19 December 2017

Fampridine MS-F203 Investigators

9

1 reference

19 December 2017

language of work or name

English

0 references

publication date

1 February 2009

1 reference

19 December 2017

published in

The Lancet

1 reference

19 December 2017

volume

373

1 reference

19 December 2017

issue

9665

1 reference

19 December 2017

page(s)

732-738

1 reference

19 December 2017

Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

4-Aminopyridine in multiple sclerosis: prolonged administration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

Aminopyridines for symptomatic treatment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

Dose comparison trial of sustained-release fampridine in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

Pharmacokinetics of an Immediate‐Release Oral Formulation of Fampridine (4‐Aminopyridine) in Normal Subjects and Patients with Spinal Cord Injury

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

The Extended Disability Status Scale (EDSS) as a predictor of impairments of functional activities of daily living in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

Day-to-day variability of maximum walking distance in MS patients can mislead to relevant changes in the Expanded Disability Status Scale (EDSS): average walking speed is a more constant parameter

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

The measurement of ambulatory impairment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

Intrarater and interrater reliability of the MS functional composite outcome measure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

Quantitative functional measures in MS: what is a reliable change?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

Short-distance walking speed and timed walking distance: redundant measures for clinical trials?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

Walking capacities in multiple sclerosis measured by global positioning system odometer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

The 25-foot walk velocity accurately measures real world ambulation in Friedreich ataxia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

Seizures in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960442-6

7 January 2021

10.1016/S0140-6736(09)60442-6

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017